Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.
Thomas Karasic, MD
Advertisement
Articles by Thomas Karasic, MD
Thomas Karasic, MD, investigator at Penn Medicine, discusses the rationale behind the phase II trial (NCT01037790) of palbociclib (Ibrance) in patients with advanced esophageal or gastric cancer.
Advertisement
Latest Updated Articles
Dr. Karasic on Palbociclib in Esophageal and Gastric CancerJanuary 29th 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
4
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
5